Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, the outweight possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than November 5, 1986.

A. Federal Reserve Bank of San Francisco (Harry W. Green, Vice President) 101 Market Street, San Francisco, California 94105:

1. *The Sumitomo Bank, Ltd.*, Osaka, Japan; to acquire JAIS-California, San Francisco, California, and thereby engage in joint venture data processing activities pursuant to § 225.25(b)(7) of the Board's Regulation Y. These activities will be conducted in the State of California.

Board of Governors of the Federal Reserve System, October 10, 1986.

James McAfee,

Associate Secretary of the Board.

[FR Doc. 86-23459 Filed 10-16-86; 8:45 am]

BILLING CODE 6210-01-M

FEDERAL TRADE COMMISSION

Consumer Protection Appliance Energy Labeling; Information Collection Requirement

AGENCY: Federal Trade Commission.

ACTION: Notice of application to OMB under the Paperwork Reduction Act, 44 U.S.C. 3507, for clearance of information collection requirements contained in an amendment to the Appliance Energy Labeling Rule, 16 CFR Part 305. An amendment of the existing clearance, OMB control No. 3084-0069, has been requested.

SUMMARY: The Appliance Energy Labeling Rule, which implements Title III of the Energy Policy and Conservation Act, 42 U.S.C. 6291, *et seq.*, requires manufacturers and importers of major energy-consuming appliances to disclose energy information to consumers by means of point-of-sale labels. The amendment extends the labeling requirement to air conditioners and heat pumps.

DATE: Comments on this application must be submitted on or before November 17, 1986.

ADDRESS: Send comments to Mr. Don Arbuckle, FTC Desk Officer, Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Room 3228, Washington, DC 20503. Copies of the application may be obtained from Public Reference Branch, Room 130, Federal Trade Commission, Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: James G. Mills, Division of Enforcement, Bureau of Consumer Protection, Federal Trade Commission, Washington, DC 20580, (202) 376-8934.

By direction of the Commission.

Emily H. Rock,

Secretary

[FR Doc. 86-23535 Filed 10-16-86; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Alcohol, Drug Abuse, and Mental Health Administration

Advisory Committees; November Meetings

AGENCY: Alcohol, Drug Abuse, and Mental Health Administration, HHS.

ACTION: Notice of meetings.

SUMMARY: This notice sets forth the schedule and proposed agenda of the forthcoming meetings of the agency's initial review committees. These committees will be open for discussion of administrative announcements and program developments. The committees will be performing initial review of applications for Federal assistance. Therefore, portions of the meetings will be closed to the public as determined by the Administrator, ADAMHA, in accordance with 5 U.S.C. 552(b)(6) and 5 U.S.C. app. 2 10(d). Notice of these meetings is required under the Federal Advisory Committee Act, Pub. L. 92-463.

Committee Name: Biological and Neurosciences Subcommittee of the Mental Health Research Education Review Committee, NIMH

Date and Time: November 6-7: 9:00 a.m.

Place: Linden Hill Hotel, 5400 Pooks Hill Road, Bethesda, Maryland 20814

Status of Meeting:

Open—November 6: 9:00-10:00 a.m.

Closed—Otherwise

Contact: Shirley Maltz, Room 9C-26, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-3936

Purpose: The Committee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research training activities in the area of biological sciences related to mental health with recommendations to the National Advisory Mental Health Council for final review.

Committee Name: Epidemiology Subcommittee of the Epidemiologic and Services Research Review Committee, NIMH

Date and Time: November 12-14: 9:00 a.m.

Place: Key Bridge Marriott, 1401 Lee Highway, Arlington, Virginia 22209

Status of Meeting:

Open—November 12: 9:00-10:00 a.m.

Closed—Otherwise

Contact: Gloria Yockelson, Room 9C14, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-1367

Purpose: The Committee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research and research training activities as they relate to mental health epidemiology, mental health service systems research, and evaluation of clinical mental health services with recommendations to the National Advisory Mental Health Council for final review.

Substantive information may be obtained from the contact persons listed above. Summaries of the meetings and rosters of committee members may be obtained as follows: NIMH: Ms. Joanna Kieffer, Committee Management Officer, Room 9-95, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-4333.

Dated: October 10, 1986.

Brenda L. Williamson,

Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 86-23454 Filed 10-16-86; 8:45 am]

BILLING CODE 4160-20-M

Centers for Disease Control

Antibiotic-Resistant Gonorrhea in the United States; Open Meeting

The Division of Sexually Transmitted Diseases (DSTD), Center for Prevention Services (CPS), Centers for Disease Control (CDC), Atlanta, Georgia, will sponsor a meeting to discuss antibiotic-resistant gonorrhea in the United States. Attendance by the public will be limited to the space available.

Date: December 2–3, 1986
Time: 8:00 a.m.–4:30 p.m.
Place: Centers for Disease Control, Building 1, Room 1003, 1600 Clifton Road, NE., Atlanta, Georgia 30333
Additional information may be obtained from: Mr. Peter Crippen, Program Services Branch, DSTD, CPS, CDC, Atlanta, Georgia 30333. Telephones: FTS: 236–1275. Commercial: (404) 329–1275.

Dated: October 10, 1986.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 86–23448 Filed 10–16–86; 8:45 am]

BILLING CODE 4160–18–M

Injury Research Grant Review Committee; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee act (Pub. L. 92–463), the Centers for Disease Control announces the following Committee meeting:

Name: Injury Research Grant Review Committee.
Dates: November 3–6, 1986
Place: Hotel Tower Place, 3340 Peachtree Road, N.E., Atlanta, Georgia 30026
Time: 8:30 a.m. — 5:00 p.m.
Type of Meeting: Open 8:30 a.m. — 9:45 a.m., November 3, 1986. Closed 1:00 a.m., November 3 — 5:00 p.m., November 6, 1986
Contract Person: Mark L. Rosenberg, M.D., Executive Secretary of the Committee, Center for Environmental Health, Centers for Disease Control, 1600 Clifton Road, N.E., Atlanta, GA 30333, Telephone: FTS: 236–4542. Commercial: (404) 454–4542
Purpose: This Committee is charged with advising the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, Centers for Disease Control, regarding the scientific merit and technical feasibility of grant applications relating to the support of injury control research and demonstration projects and injury prevention research centers.
Agenda: Agenda items for the meeting will include announcements, discussion of review procedures, future meeting dates, and review of grant applications. Beginning at 10:00 a.m., Monday, November 3, through 5:00 p.m., Wednesday, November 6, the Committee will conduct its review of grant applications. This portion of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(6), Title 5 U.S. Code, and the Determination of the Director, Centers for Disease Control, pursuant to Pub. L. 92–463.

Agenda items are subject to change as priorities dictate.

Dated: October 10, 1986.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 86–23450 Filed 10–16–86; 8:45 am]

BILLING CODE 4160–18–M

Fall Hazards Associated With Erection of Painted Steel Structural Members; Open Meeting

The following meeting will be convened by the National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control (CDC) and will be open to the public for observation and participation, limited only by the space available:

Date: November 20, 1986
Time: 10 a.m.–3 p.m.
Place: Room 138–B, Appalachian Laboratory for Occupational Safety and Health, 944 Chestnut Ridge Road, Morgantown, West Virginia 26505
Purpose: To discuss a study to be conducted by the University of Oklahoma pursuant to a contract with NIOSH. This study is to correlate quantitative measurements of the coefficient of friction of painted structural steel members, under various conditions, with the subjectively determined workers' acceptability of slipperiness. Viewpoints and suggestions from industry, organized labor, academia, other government agencies, and the public are invited.
Additional information may be obtained from: Ronald Stanevich, Division of Safety Research, NIOSH, CDC, 944 Chestnut Ridge Road, Morgantown, West Virginia 26505–2888, Telephones: FTS: 923–4531. Commercial: 304/291–4531

Dated: October 10, 1986.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 86–23449 Filed 10–16–86; 8:45 am]

BILLING CODE 4160–19–M

Food and Drug Administration

[Docket No. 86F–0362]

Betz Laboratories; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Betz Laboratories has filed a petition proposing that the food additive regulation for boiler water additives be amended to provide for the safe use of a copolymer of methacrylic acid and acrylic acid as an active polymer in boiler water.

FOR FURTHER INFORMATION CONTACT: John W. Gordon, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–426–5487.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 6A3957) has been filed on behalf of Betz Laboratories, Somerton Rd., Trevose, PA 19047, proposing that § 173.310 *Boiler water additives* (21 CFR 173.310) be amended to provide for the safe use of a copolymer of methacrylic acid and acrylic acid as an active polymer in boiler water.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: October 3, 1986.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 86–23451 Filed 10–16–86; 8:45 am]

BILLING CODE 4160–01–M

Advisory Committees; Meetings

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

Meetings: The following advisory committee meetings are announced:

General Hospital and Personal Use Devices Panel

Date, time, and place. November 3, 9 a.m., Rm. 503A, Hubert H. Humphrey

Bldg., 200 Independence Ave. SW. Washington, DC.

Type of meeting and contact person. Open public hearing, 9 a.m. to 10 a.m.; open committee discussion, 10 a.m. to 11 a.m.; closed peresentation of data, 11 a.m. to 12 m.; closed committee deliberations, 1:30 p.m. to 2:30 p.m.; open committee discussion, 2:30 p.m. to 4 p.m.; Andrea A. Wargo, Center for Devices and Radiological Health (HFZ–420), Food and Drug Administration, 8757 Georgia Ave., Silver Spring, MD 20910, 301–427–7750.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before October 27, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss safety and effectiveness data for a programmable implantable infusion pump.

Closed presentation of data. Trade secret and/or confidential commercial information will be presented to the committee regarding materials, computer software, and manufacturing information. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Closed committee deliberations. The committee will discuss trade secret and/or confidential commercial information on materials, computer software, and manufacturing information. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Radiologic Devices Panel

Date, time, and place. November 24, 9 a.m., Rm. 416, 12720 Twinbrook Parkway, Rockville, MD.

Type of meeting and contact person. Open public hearing, 9 a.m. to 10 a.m.; open committee discussion, 10 a.m. to 11 a.m.; closed committee deliberations, 11 a.m. to 12 a.m.; open committee discussion, 1 p.m. to 4:30 p.m.; Robert Phillips, Center for Devices and Radiological Health (HFZ–430), Food and Drug Administration, 8757 Georgia Ave, Silver Spring, MD 20910, 301–427–7514.

General function of the committee. The committee reviews and evaluates available data on the safety and effectiveness of devices and makes recommendations for their regulation.

Agenda—Open public hearing. Interested persons may present data, information, or veiws, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before November 17, and submit a brief statement of the general nature of the evidence or agruments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open committee discussion. The committee will discuss premarket approval applications for magnetic resonance imaging devices. The committee will also discuss the requirements for reclassification of devices and generalized requirements for magnetic resonance imaging device premarket approval applications.

Closed committee deliberations. The committee may discuss trade secret and/or confidential commercial information relevant to premarket approval applications for magnetic resonance imaging devices. This portion of the meeting will be closed to permit discussion of this information (5 U.S.C. 552b(c)(4)).

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (Subpart C of 21 CFR Part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR Part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's descretion.

Persons interested in specific agenda items to be discussed in open session may ascertain from the contact person the approximate time of discussion.

A list of committee members and summary minutes of meetings may be requested from the Dockets Management Branch (HFA–305), Rm. 4–62, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

The Commissioner, with the concurrence of the Chief Counsel, has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA), as amended by the Government in the Sunshine Act (Pub. L. 94–409), permits such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in

certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, notably deliberative sessions to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)), and FDA's regulations (21 CFR Part 14) on advisory committees.

Dated: October 10, 1986.

Frank E. Young,

Commissioner of Food and Drugs.

[FR Doc. 86–23452 Filed 10–16–86; 8:45 am]

BILLING CODE 4160–01–M

Health Care Financing Administration

Statement of Organization, Functions, and Delegations of Authority

Part F. of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Health Care Financing Administration (HCFA), **Federal Register**, Vol. 51, No. 138, pg. 26060–26062, dated Friday, July 18, 1986) is amended to reflect a revision to the Division and Medicare Payments II functional statement. This change will emphasize the financial analysis responsibilities of the division and will help distinguish the difference in functions between the two Medicare Payments Divisions in the Office of Financial Management, Office of Prepaid Health Care.

The specific changes are:

• Section FC.20.D.3., Division of Medicare Payments II, is deleted in its entirety and replaced by a new functional statement for the division to read as follows:

3. Division of Medicare Payments II (FCC3).

Responsible for all activities which involve Medicare prepaid health plan accounting policy implementation and payments for Regions VI through X. Reviews and approves Adjusted Community Rate (ACR) proposals for contractor reimbursement on a risk basis as set out under the Tax Equity and Fiscal Responsibility Act. Provides training for "risk" contractors on the technicalities of ACR determinations. Conducts onsite visits to review contractors' documentation for ACR computations and the overall assessment of contractors' accounting operations. Renders technical guidance, coordinates appeals, and provides assistance concerning prepayment plan cost reimbursement and audit. Recommends new procedures to improve operations, such as guidelines for targeting prepaid health plan audits. Coordinates payment policy formulation with the Bureau of Program Policy and the Office of the Actuary. Reviews health maintenance organizations' annual budget and enrollment forecasts, quarterly cost reports, and final cost reports. Prepares information for sending requests for proposals to independent certified public accounting (CPA) firms, reviews audit reports from CPA firms, and negotiates settlement of audit exceptions with prepaid health plans. Develops and maintains reimbursement forms and manuals, and inteprets reimbursement policy applicable to individual accounting situations. Determines interim payments due prepaid health plans, schedules payments accordingly, and maintains records of payments made. Reviews and analyzes national data on an ongoing basis for the purpose of monitoring prepaid health care in the areas of plan enrollment and payments. Develops and implements an ongoing analysis and review of operational/policy areas that impact upon the office's financial operations.

Dated: September 26, 1985.

Bartlett S. Fleming,

Associate Administrator for Management and Support Services.

[FR Doc. 86–23477 Filed 10–16–86; 8:45 am]

BILLING CODE 4120–03–M

Statement of Organization, Functions, and Delegations of Authority

Part F. of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Health Care Financing Administration, (**Federal Register**, Vol. 49, No. 133, pg. 28120, dated Tuesday, July 10, 1984 and **Federal Register**, Vol. 48, No. 3, dated Wednesday, January 5, 1983), is amended to reflect a change in the organizational structure of the Office of Coverage Policy (OCP), Bureau of Eligibility, Reimbursement and Coverage, Office of the Associate Administrator for Program Development. OCP is being reorganized to reflect additional responsibilities and the consolidation of all currently fragmented aspects of coverage policy pertaining to providers and suppliers of services. The Division of Provider and Supplier Standards (DPSS) will be abolished. The function of DPSS will be divided among the remaining two divisions, the Division of Medical Services Coverage Policy and the Division of Provider Services Coverage Policy.

The specific amendments to Part F. are described below:

• Section FQ.20.3.Q, Division of Provider Services Coverage Policy (FQA71), is deleted in its entirety and replaced by the following:

a. Division of Provider Services Coverage Policy (FQA71).

Develops, evaluates, and reviews national policies and standards concerning the coverage of services and the conditions of participation under Medicare, Medicaid, and other Federal programs for hospitals, skilled nursing facilities (SNFs), intermediate care facilities (ICFs), Christian Science Sanitoriums, home health agencies (HHAs), hospices, and other providers of services. Develops, evaluates, and reviews national policies concerning the coverage of mental health, alcoholism and drug treatment, medical day care, family planning, sterlization, abortion and teenage pregnacy, early and periodic screening, diagnois and treatment (EPSDT), personal care and Indian health services, utilization review, physician certification and prior authorization requirements, and the